Jafron Biomedical Co.,Ltd. (300529.SZ) SHZ
Currency In CNY
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In CNY
Sector
Healthcare
Industry
Medical - Devices
Employees
2797
First IPO Date
August 02, 2016
| Name | Title | Pay | Year Born |
| Aijun Wu | Vice President | 0 | 1965 |
| De Zhi Li | Vice President | 0 | 1966 |
| Feng Li | VP & Non-Independent Director | 0 | 1970 |
| Rui Wang | General Manager | 0 | 1962 |
| Cong Huang | Board Secretary | 0 | 1992 |
| Xian Min Tang | VP & Director | 0 | 1970 |
| Xueyun Liao | Director & Financial Director | 0 | 1977 |
| Fan Dong | Chairman of Board of Directors & GM | 0 | 1970 |
Established in 1989 and headquartered in Zhuhai, China, Jafron Biomedical Co.,Ltd. is a key player in the research, development, manufacturing, and commercialization of advanced biological materials and medical devices. The company specializes in providing innovative solutions for a range of critical health issues, including kidney, liver, critical, and rheumatic diseases, as well as various forms of poisoning. Its primary product lines feature sophisticated adsorption technologies and blood purification systems. Beyond these core offerings, Jafron's extensive portfolio also encompasses essential medical supplies such as single-use arteriovenous puncture needles, hemodialysis online dry powder bags/cylinders, disinfectants, hemodialysis concentrates, and medical absorbable sutures with needles. Globally, Jafron Biomedical has a significant presence, distributing its products across countries like Germany, Italy, Turkey, Thailand, Vietnam, the Philippines, South Africa, Kenya, Chile, Peru, and the United Arab Emirates.